Buy AUPH by Oct 2, 2026.

**Is anyone else looking at Aurinia Pharmaceuticals (AUPH)? What am I missing?** I’ve been digging into Aurinia over the past week, and honestly, I’m surprised it isn’t discussed more often. Here’s why it caught my attention: The company is already profitable, which is pretty rare for a biotech of this size. Revenue is still growing at a healthy pace, and they continue to generate positive cash flow. They have around **$379M in cash**, so they don’t seem to be in …